Osteoprotegerin, vascular calcification and atherosclerosis.
about
Gestational Diabetes Mellitus and Future Cardiovascular Risk: An UpdatePeripheral and central arterial pressure and its relationship to vascular target organ damage in carotid artery, retina and arterial stiffness. Development and validation of a tool. The Vaso risk studyElevated osteoprotegerin is associated with abnormal ankle brachial indices in patients infected with HIV: a cross-sectional studyDiscordant gene expression signatures and related phenotypic differences in lamin A- and A/C-related Hutchinson-Gilford progeria syndrome (HGPS).Serum osteopontin level correlates with carotid-femoral pulse wave velocity in geriatric personsOsteoprotegerin CGA haplotype protection against cerebrovascular complications in anti-CCP negative patients with rheumatoid arthritisImmune activation, immunosenescence, and osteoprotegerin as markers of endothelial dysfunction in subclinical HIV-associated atherosclerosis.Osteoprotegerin deficiency limits angiotensin II-induced aortic dilatation and rupture in the apolipoprotein E-knockout mouse.Pro-inflammatory profile of preeclamptic placental mesenchymal stromal cells: new insights into the etiopathogenesis of preeclampsia.Osteoprotegerin in exosome-like vesicles from human cultured tubular cells and urineAssociation of circulating sclerostin with vascular calcification in Afro-Caribbean men.Magnesium inhibits Wnt/β-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells.Long Term Effect of High Glucose and Phosphate Levels on the OPG/RANK/RANKL/TRAIL System in the Progression of Vascular Calcification in rat Aortic Smooth Muscle CellsInflammatory biomarkers, cerebral microbleeds, and small vessel disease: Framingham Heart Study.Shared genetic architecture in the relationship between adult stature and subclinical coronary artery atherosclerosis.The Effects of Atorvastatin on Arterial Stiffness in Male Patients with Type 2 DiabetesIncreased expression of angiogenic and inflammatory proteins in the vitreous of patients with ischemic central retinal vein occlusion.Osteoprotegerin in Cardiometabolic Disorders.Correlation of increased plasma osteoprotegerin and cardiovascular risk factors in patients with adult growth hormone deficiency.Osteoprotegerin in relation to insulin resistance and blood lipids in sub-Saharan African women with and without abdominal obesity.Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes.Higher Levels of Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and Endovascular Damage in HIV-Suppressed Patients.Serum osteoprotegerin is associated with pulse pressure in kidney transplant recipientsOsteoprotegerin, but Not Receptor Activator for Nuclear Factor-κB Ligand, is Associated With Subclinical Coronary Atherosclerosis in HIV-Infected MenPrognostic impact of alkaline phosphatase measured at time of presentation in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis.Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study.Calcium and osteoprotegerin levels predict the progression of the abdominal aortic calcifications after kidney transplantation.Human coronary artery perivascular adipocytes overexpress genes responsible for regulating vascular morphology, inflammation, and hemostasisOsteoprotegerin, Soluble Receptor Activator of Nuclear Factor- κ B Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus.Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.Therapeutic implications of osteoprotegerin.Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin.Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis.Tumor necrosis factor superfamily molecules in acute coronary syndromes.Coronary calcification and hormones.Mechanisms and treatment of extraosseous calcification in chronic kidney disease.Proinflammatory phenotype of perivascular adipocytes.
P2860
Q28067405-D19E635B-B0F5-4100-8A78-EB169AA979A4Q31007504-07E62225-C199-4AF0-ADCE-72E9AC616878Q33811250-3D2A3DD4-D4BA-4F56-A641-F56F08D9D08AQ33954902-C01FCE01-7C36-4122-BFEC-5C5E41AE8941Q34009369-28BF7988-7271-4320-99A2-758267EE7E21Q34128912-2C685AF5-8287-4207-8840-D2469EE26353Q34412603-93BA5606-E4CD-4922-9042-CF7550EDE19FQ34550560-163A35F1-B25D-4C8E-9C8E-E83046587E5CQ34635145-E1012AAD-24A2-4D12-A066-70D9863759CCQ34994210-14C14C18-FD05-4897-A1DB-7BB6822364ECQ35091260-FABC2ECC-2A40-4905-B353-008F6AB0F7BBQ35107539-1B8A17A4-2CED-497A-A16E-63A062D35D15Q35127451-3B2E2A16-08D8-4ECB-ABAA-F34BED67283AQ35134908-B0461C2F-0D87-4A4E-ACDC-34FDBD55DDFAQ35581238-E17FBC17-3EF0-4025-B92E-6ADF2065B962Q35603481-45DAECBB-D30C-404F-9111-A9D0017C9913Q35610722-D5B95A47-D6EF-429B-BC53-5DF919AE3A40Q35640787-9DDA6E8D-D1E9-4B94-96EF-DC36C2722757Q35643468-4A724D7D-A9E4-423F-9007-8EFD7AC82490Q35669454-5CA28249-58A7-4A0C-9DE5-950B88C824CDQ35926521-051008EC-2E55-4D78-9546-65E5DA6A61C1Q35935297-A527FE24-C8AD-4207-93D1-D529BCEF6081Q36149956-6C4BC21F-0DAE-4EC0-98CF-F7B2BE9F1D69Q36219767-612F380A-2847-4F68-A08F-E234B818637AQ36275393-98A00F09-F722-49AF-855C-948B48666D8AQ36388215-E65201C9-4272-40D5-84A4-F5230CEFE868Q36576768-CE1FAF4C-7ADF-4315-AB19-1C773D222EF8Q36842216-7C52B151-A0F9-4ABD-8554-60746AABAAA7Q37020312-76B4219C-EEAF-47E2-B861-FA82E9164FDDQ37093829-7B90B824-1A63-41C5-BFD4-3E85D0210475Q37322445-3A902296-8FDC-4197-BAE3-CFD87878E400Q37344527-6CEEFC0F-8433-44E6-B6D5-4ADDD4936FFEQ37368570-5CD0E3A8-322A-4A13-9B02-E073DD96AAF6Q37408169-C5CEDDE0-356A-4FF7-8431-EC4DFD5A5473Q37428071-D4802121-A17A-4967-A7C2-DCDD105A9692Q37686803-EC74C771-2D0D-4844-8C3A-1CC8623133F3Q37805514-F2BC8DA2-815C-49E3-9860-59FC957DC2D8Q37855315-69DFBBE1-273D-443E-ABB6-BC78299A3219Q37902504-74D6AD09-8BA2-4E5F-BECF-4A10F93A9249Q38219956-135B2F5C-D45E-4A14-B88D-2D49BABD334D
P2860
Osteoprotegerin, vascular calcification and atherosclerosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Osteoprotegerin, vascular calcification and atherosclerosis.
@en
Osteoprotegerin, vascular calcification and atherosclerosis.
@nl
type
label
Osteoprotegerin, vascular calcification and atherosclerosis.
@en
Osteoprotegerin, vascular calcification and atherosclerosis.
@nl
prefLabel
Osteoprotegerin, vascular calcification and atherosclerosis.
@en
Osteoprotegerin, vascular calcification and atherosclerosis.
@nl
P2860
P1433
P1476
Osteoprotegerin, vascular calcification and atherosclerosis.
@en
P2093
Ann Van Campenhout
P2860
P304
P356
10.1016/J.ATHEROSCLEROSIS.2008.09.033
P577
2008-10-09T00:00:00Z